Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, ...
Aug 5, 2021
0
238
Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments—and wildly different outcomes for patients as a result.
Jun 7, 2021
0
15
Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors—tumors that often spread and are difficult to treat.
May 26, 2021
0
11
A multi-institutional team of researchers has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
Apr 26, 2021
0
58
Lung carcinomas are the leading cause of cancer-related deaths in the United States and worldwide. Lung squamous cell carcinomas (non-small cell lung cancers that arise in the bronchi of the lungs and make up approximately ...
Apr 26, 2021
0
97
Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount ...
Mar 24, 2021
0
63
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from the UCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness ...
Mar 23, 2021
0
46
A chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this ...
Mar 15, 2021
0
35
Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery.
Feb 2, 2021
0
93
Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant ...
Jan 19, 2021
0
70
